Skip to main content

Table 2 Clinicopathological variables of ruptured HCC patients who underwent hepatectomy with hepatic inflow occlusion(HIO) and without hepatic inflow occlusion(non-HIO) after PSM

From: The effect of the number of hepatic inflow occlusion times on the prognosis of ruptured hepatocellular carcinoma patients after hepatectomy

Variables

Non-hepatic inflow occlusion

Hepatic inflow occlusion

p-value

n = 80

n = 80

Gender (%)

  

0.175

 Male

65 (81.3)

72 (90.0)

 

 Female

15 (18.7)

8 (10.0)

 

Age (y)

45.6 ± 11.4

44.4 ± 11.3

0.568

Length (%)

  

0.858

  ≤ 5 cm

21 (26.3)

22 (27.5)

 

  > 5 cm

59 (73.8)

58 (72.5)

 

Tumor number (%)

  

0.855

 Single

61 (76.3)

59 (73.8)

 

 Multiple

19 (23.8)

21 (26.3)

 

BCLC stage (%)

  

1.000

 A

48 (60.0)

48 (60.0)

 

 B

20 (25.0)

20 (25.0)

 

 C

12 (15.0)

12 (15.0)

 

Child–Pugh (%)

  

0.454

 A

64 (80.0)

59 (73.8)

 

 B

16 (20.0)

21 (26.3)

 

AFP (%)

  

0.748

  ≤ 400 ng/ml

31 (38.8)

34 (42.5)

 

  > 400 ng/ml

49 (61.3)

46 (57.5)

 

Edmondson-steiner (%)

  

0.091

 I

11 (13.8)

7 (8.8)

 

 II

28 (35.0)

43 (53.8)

 

 III

26 (32.5)

16 (20.0)

 

 IV

15 (18.8)

14 (17.5)

 

Necrosis (%)

  

0.205

 No

56 (70.0)

63 (78.8)

 

 Yes

24 (30.0)

17 (21.3)

 

Local invasion (%)

  

0.635

 No

36 (45.0)

40 (50.0)

 

 Yes

44 (55.0)

40 (50.0)

 

ALB (g/L)

35.3 (32.3–38.1)

35.6 (32.9–37.8)

0.889

ALT (U/L)

27.0 (21.0–43.3)

30.5 (24.0–44.0)

0.321

AST (U/L)

37.5 (28.5–63.5)

35.0 (22.3–65.8)

0.512

ALP (U/L)

76.0 (54.5–94.5)

76.5 (61.0–91.0)

0.475

GGT (U/L)

49.5 (28.0–93.3)

51.5 (35.0–126.8)

0.280

HBsAg (%)

  

0.159

 No

14 (17.5)

7 (8.8)

 

 Yes

66 (82.5)

73 (91.3)

 
  1. BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; HIO, hepatic inflow occlusion; PSM, Propensity Score Matching